Time-Limited Zanubrutinib/Rituximab Yields Durable Remissions in Treatment-Naive CLL
TAR-200 Is Poised to Become a Targeted, Tolerable Addition to BCG-Unresponsive NMIBC Treatment Arsenal
Efineptakin Alfa Represents Potentially Effective Option in Kaposi Sarcoma
Orca-T Promotes T-Cell Activation in Hematologic Malignancies